Dimensional Fund Advisors LP Has $137,000 Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Dimensional Fund Advisors LP cut its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 8.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,548 shares of the company’s stock after selling 5,180 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Acumen Pharmaceuticals were worth $137,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Chicago Partners Investment Group LLC lifted its position in shares of Acumen Pharmaceuticals by 34.9% during the fourth quarter. Chicago Partners Investment Group LLC now owns 18,315 shares of the company’s stock valued at $70,000 after purchasing an additional 4,736 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Acumen Pharmaceuticals in the 1st quarter worth approximately $52,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Acumen Pharmaceuticals in the first quarter worth $253,000. Price T Rowe Associates Inc. MD purchased a new position in Acumen Pharmaceuticals during the 1st quarter valued at $4,449,000. Finally, Gladius Capital Management LP purchased a new stake in shares of Acumen Pharmaceuticals in the 2nd quarter worth about $26,000. 71.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on ABOS shares. UBS Group dropped their price target on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Acumen Pharmaceuticals in a research report on Thursday, October 3rd. Finally, Citigroup raised shares of Acumen Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

Acumen Pharmaceuticals Stock Performance

Shares of Acumen Pharmaceuticals stock opened at $2.33 on Wednesday. Acumen Pharmaceuticals, Inc. has a one year low of $1.81 and a one year high of $5.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 17.37 and a current ratio of 17.37. The company has a market capitalization of $139.99 million, a PE ratio of -2.20 and a beta of 0.07. The company has a 50-day simple moving average of $2.54 and a two-hundred day simple moving average of $2.89.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Research analysts expect that Acumen Pharmaceuticals, Inc. will post -1.32 EPS for the current fiscal year.

Acumen Pharmaceuticals Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.